	, , , , , , , , , , , , , , , , , , , ,							
⊡FORM F	PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK AND A AFFORMEY SOUCKE PHUMBER							
OFFICE (M	MODIFIED) X-16455							
	ANSMITTAL LETTER TO THE UNITED STATES  U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)							
	DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371							
	RNATIONAL APPLICATION NO.   INTERNATIONAL FILING DATE   PRIORITY DATE CLAIMED							
	PCT/US2005/000023 19 January 2005 (19.01.2005) 26 January 2004 (26.01.2004)							
	OF INVENTION: USE OF FGF-21 AND THIAZOLIDINEDIONE FOR TREATING TYPE 2 DIABETES							
	ANT(S) FOR DO/EO/US: Alexei KHARITONENKOV and Tatiyana Leonidovna SHIYANOVA t herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information:							
1.	X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.							
2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.							
3.	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay							
г	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).							
4.	X The US has been elected (Article 31).							
5.	A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
	a. is transmitted herewith (required only if not transmitted by the International Bureau).							
	b. has been transmitted by the International Bureau.							
	c. X is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.	A translation of the International Application into English (35 U.S.C. 371(c)(2)).							
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))							
	a. are transmitted herewith (required only if not transmitted by the International Bureau).							
	b. have been transmitted by the International Bureau.							
	c. have not been made; however, the time limit for making such amendments has NOT expired.							
_	d. X have not been made and will not be made.							
8.	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.	X A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form.							
11.	A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an							
	English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)).							
	to 18. below concern document(s) or information included:  X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. X Search Report/Written Opinion (ISA/EP)							
13.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
14.	Assignment has been recorded at reel, frame							
15.	A FIRST preliminary amendment.							
	A SECOND or SUBSEQUENT preliminary amendment.							

"This is the national phase application, under 35 USC 371, for PCT/US2005/000023, filed 19 January 2005, which claims the benefit, under 35 USC 119(e), of US provisional application 60/539,241, filed 26 January

Please amend the first page of the specification by inserting the following cross-reference after the title:

A Sequence Listing, 1.821 Statement, and diskette.

A power of attorney with 3.73(b) certificate.

Other items or information:

2004."

16.

17.

18.

AP20 Rec'd PCT/PTO 21 JUL 2006

II C ADI	LICATION NO. COL	own, see 37 C.F.R. 4.5)		ADDITION A		ATTORNEY'S DOC	TVET NI IMPED	
U.Ş. APF	10/58		INTERNATIONAL PCT/US2	2005/000023	10.	X-16		
19.	X The following fees are submitted:					CALCULATIONS PTO USE ONLY		
(a)	Basic national fee	(37 CFR 1.492(a))\$300.00				300.00		
(b)	Examination fee (37 CFR 1.492(c))  If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)							
						200.00		
(c)	Search fee (37 CFI If the written opini examination report provisions of PCT	\$	400.00					
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority\$100  International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB\$400								
	1	•	•					
	All other situations	S			╁	·		
	54120.00.5		TOTAL AMOUN		<u> </u>	900.00		
		furnishing the oath or priority date (37 CFR)	declaration later than 30 i	months	\$		-	
HOIII ti	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE				
Total claims		8 -20=	0	X \$50.0	) \$	:		
Independent claims		1 -3=	0	X \$200.0	) \$	<del>-</del>		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00								
		TOTAL	OF ABOVE CALO	CULATIONS =	= \$			
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).						÷.		
SUBTOTAL =						900.00		
Processing fee of \$130.00 for furnishing English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						000.00		
TOTAL NATIONAL FEE = Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be						900.00		
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).  \$40.00 per property +								
			TOTAL FEES	<b>ENCLOSED</b> =	= \$			
						Amount to be refunded	Ψ	
		· -			_L_	charged	\$	
a. b.	X Please charge copy of this	ge my Deposit Accoun sheet is enclosed.	to cover the above fet No. 05-0840 in the amountained to above any additional to a bove and a bove a bove and a bove and a bove and a bove a bove and a bove and a bove and a bove and a bove a bove a bove and a bove a bove a bove a bove a bove and a bove a	unt of <u>\$ <b>900.00</b></u> to				
c.	overpaymen	t to Deposit Account I	orized to charge any addit No. 05-0840. A duplicate der 37 CFR 1.494 or 1.49	copy of this sheet	is er	iclosed.		
	(37 CFR 1.137(a	a) or (b)) must be file	d and granted to restore					
ELI LI PATEN P.O. BO	ALL CORRESPONE LLY AND COMPA IT DIVISION DX 6288 NAPOLIS, INDIANA	<b>25885</b>						
	DATE 45,341  REGISTRATION	1	SIGNATUR Lynn D. Ape  317-276-65  TELEPHONE NU	501		PATENT TRADEMARK		

## 10/587138 AP20 Rec'd PCT/PTO 21 JUL 2006

## IN THE UNITED STATES RECEIVING OFFICE (USRO)

Applicants: Alexei KHARITONENKOV

Tatiyana Leonidovna SHIYANOVA

International Application No.: PCT/US2005/000023

Filed: 19 January 2005 (19.01.2005)

Invention: USE OF FGF-21 AND THIAZOLIDINENDIONE FOR TREATING TYPE 2 DIABETES

Lilly Reference:

X-16455

Earliest Priority Date: 26 January 2004 (26.01.2004)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

"Express Mail" mailing label number: <u>EV 393133915 US</u>

Date of Deposit: Lely 21, 206

I hereby certify that the following attached paper or fee

Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.